DD229713A5 - Verfahren zur herstellung von gereinigtem htnf - Google Patents

Verfahren zur herstellung von gereinigtem htnf Download PDF

Info

Publication number
DD229713A5
DD229713A5 DD84264523A DD26452384A DD229713A5 DD 229713 A5 DD229713 A5 DD 229713A5 DD 84264523 A DD84264523 A DD 84264523A DD 26452384 A DD26452384 A DD 26452384A DD 229713 A5 DD229713 A5 DD 229713A5
Authority
DD
German Democratic Republic
Prior art keywords
htnf
cells
tnf
human
cell
Prior art date
Application number
DD84264523A
Other languages
German (de)
English (en)
Inventor
Lloyd J Old
Eleizabeth C Richards
Berish Y Rubin
Barbara D Williamson
Jay S Prendergast
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of DD229713A5 publication Critical patent/DD229713A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DD84264523A 1983-06-27 1984-06-26 Verfahren zur herstellung von gereinigtem htnf DD229713A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50847283A 1983-06-27 1983-06-27

Publications (1)

Publication Number Publication Date
DD229713A5 true DD229713A5 (de) 1985-11-13

Family

ID=24022900

Family Applications (3)

Application Number Title Priority Date Filing Date
DD84264523A DD229713A5 (de) 1983-06-27 1984-06-26 Verfahren zur herstellung von gereinigtem htnf
DD84286074A DD241271A5 (de) 1983-06-27 1984-06-26 Verfahren zur unterscheidung von normalen und boesartigen zellen in einer mischung in vitro
DD86286075A DD241268A5 (de) 1983-06-27 1986-01-09 Verfahren zur herstellung von gegen htnf resistenten maeuse-l(r)-zellen

Family Applications After (2)

Application Number Title Priority Date Filing Date
DD84286074A DD241271A5 (de) 1983-06-27 1984-06-26 Verfahren zur unterscheidung von normalen und boesartigen zellen in einer mischung in vitro
DD86286075A DD241268A5 (de) 1983-06-27 1986-01-09 Verfahren zur herstellung von gegen htnf resistenten maeuse-l(r)-zellen

Country Status (15)

Country Link
EP (1) EP0131789A3 (en:Method)
JP (1) JPS6036420A (en:Method)
KR (1) KR850000528A (en:Method)
AU (1) AU587959B2 (en:Method)
CA (1) CA1265444A (en:Method)
DD (3) DD229713A5 (en:Method)
DK (1) DK311984A (en:Method)
ES (2) ES8603949A1 (en:Method)
FI (1) FI842560A7 (en:Method)
GR (1) GR82260B (en:Method)
HU (2) HU197358B (en:Method)
NO (1) NO842572L (en:Method)
NZ (1) NZ208648A (en:Method)
PT (1) PT78773B (en:Method)
ZA (1) ZA844377B (en:Method)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
JPS59141519A (ja) * 1983-01-31 1984-08-14 Otsuka Pharmaceut Co Ltd 制ガン作用を有する蛋白質
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
JPS60243018A (ja) * 1984-05-17 1985-12-03 Yamanouchi Pharmaceut Co Ltd ヒト内来性癌制御因子
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US6686455B1 (en) 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
GR851626B (en:Method) * 1984-07-05 1985-11-26 Genentech Inc
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
EP0313104A3 (en) * 1984-12-21 1989-07-12 Biogen, Inc. Purification, production and use of tumor necrosis factors
EP0205038A1 (en) * 1985-05-29 1986-12-17 Suntory Limited Polypeptide, process for preparing it, microorganism and pharmaceutical use
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
DE102012024749A1 (de) * 2012-12-11 2014-06-26 Martin Röcken Tumorprävention und -therapie durch Induktion einer Tumorseneszenz

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2513124B1 (fr) * 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
GR851626B (en:Method) * 1984-07-05 1985-11-26 Genentech Inc

Also Published As

Publication number Publication date
DK311984D0 (da) 1984-06-26
CA1265444A (en) 1990-02-06
FI842560L (fi) 1984-12-28
DD241271A5 (de) 1986-12-03
ES545258A0 (es) 1986-07-16
KR850000528A (ko) 1985-02-27
PT78773A (en) 1984-07-01
JPS6036420A (ja) 1985-02-25
FI842560A7 (fi) 1984-12-28
AU2933784A (en) 1985-01-03
NZ208648A (en) 1989-07-27
ES533767A0 (es) 1986-01-01
AU587959B2 (en) 1989-09-07
EP0131789A2 (en) 1985-01-23
EP0131789A3 (en) 1986-12-03
FI842560A0 (fi) 1984-06-26
NO842572L (no) 1984-12-28
ZA844377B (en) 1985-05-29
DD241268A5 (de) 1986-12-03
PT78773B (en) 1986-06-26
DK311984A (da) 1984-12-28
GR82260B (en:Method) 1984-12-13
HUT34775A (en) 1985-04-28
ES8603949A1 (es) 1986-01-01
HU197358B (en) 1989-03-28
HU201680B (en) 1990-12-28
ES8608885A1 (es) 1986-07-16

Similar Documents

Publication Publication Date Title
DD229713A5 (de) Verfahren zur herstellung von gereinigtem htnf
DE3689246T2 (de) Physiologisch aktives Polypeptid BUF-3.
DE3227262C2 (en:Method)
Storb et al. Treatment of established human graft-versus-host disease by antithymocyte globulin
DE3520228C2 (de) Wasserlösliche bioaktive Trockenfeststoffzusammensetzung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
DE69328558T2 (de) Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen
DE69533941T2 (de) Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
DE69026620T2 (de) Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor-agonisten
DE69713485T2 (de) Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
DE3001585A1 (de) Verfahren zur herstellung von interferon typ ii und es enthaltende zubereitungen
DE3781204T2 (de) Verfahren zur herstellung von lymphokinaktivierten toetenden zellen.
Evans Lymphotoxin—an immunologic hormone with anticarcinogenic and antitumor activity
DE69430059T2 (de) Freisetzung und Mobilisierung hämatopoietischer Zellen
DD209634A5 (de) Verfahren zur herstellung neuer glykoproteine und deren verwendung in therapeutischen mitteln gegen tumore
DE2628914C2 (en:Method)
DE69634982T2 (de) Verfahren zur steigerung von hematopoietischen zellen
DE69213943T2 (de) Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern
DE9390311U1 (de) Neue Makrophagen mit Eignung als Wirkstoffe von pharmazeutischen Zusammensetzungen
DE69533873T2 (de) Krebstherapie mit lymphotoxin
DE2645993C2 (en:Method)
DE69116321T2 (de) Immunostimulierendes Mittel das Interleukin-2 und 5'-Deoxy-5-fluorouridin enthält
DE3875859T2 (de) Zubereitungen zur verbesserung der adcc-therapien.
DE69112573T2 (de) Immunstimulierendes arzneimittel, das polare glycopeptidolipide von mycobakterium-chelonae enthält.
DE69527640T2 (de) Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten
DE69429657T2 (de) Verwendung von modifizierten tall-104 zellen zur behandlung von krebs und viralen krankheiten

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee